Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02655-6
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee - Oral Session (O167-O168).","authors":"","doi":"10.1038/s41409-025-02655-6","DOIUrl":"https://doi.org/10.1038/s41409-025-02655-6","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"973-974"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02649-4
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007).","authors":"","doi":"10.1038/s41409-025-02649-4","DOIUrl":"https://doi.org/10.1038/s41409-025-02649-4","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"11-18"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02658-3
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Quality Management Group - Oral Session (O169).","authors":"","doi":"10.1038/s41409-025-02658-3","DOIUrl":"https://doi.org/10.1038/s41409-025-02658-3","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"996-997"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02646-7
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Lectures.","authors":"","doi":"10.1038/s41409-025-02646-7","DOIUrl":"https://doi.org/10.1038/s41409-025-02646-7","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"4-5"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02656-5
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee - Poster Session (P919-P930).","authors":"","doi":"10.1038/s41409-025-02656-5","DOIUrl":"https://doi.org/10.1038/s41409-025-02656-5","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"975-984"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02660-9
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium - Poster Session (P965-P969).","authors":"","doi":"10.1038/s41409-025-02660-9","DOIUrl":"https://doi.org/10.1038/s41409-025-02660-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"1013-1016"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02654-7
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group - Poster Session (910-918).","authors":"","doi":"10.1038/s41409-025-02654-7","DOIUrl":"https://doi.org/10.1038/s41409-025-02654-7","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"967-972"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-30DOI: 10.1038/s41409-025-02722-y
Anna Torrent, Mireia Morgades, Gloria Iacoboni, Juan Luis Reguera, Mi Kwon, Lucia López Corral, Rafael Hernani, Valentín Ortiz-Maldonado, Jaime Sanz, Ana Carolina Caballero Gonzalez, Luisa Guerra, José María Sánchez Pina, Alberto Mussetti, Alejandro Martin Garcia-Sancho, Mariana Bastos-Oreiro, Javier Delgado, Cecilia Carpio, Juan-Manuel Sancho, Antonio Pérez-Martinez, Pere Barba
{"title":"Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy","authors":"Anna Torrent, Mireia Morgades, Gloria Iacoboni, Juan Luis Reguera, Mi Kwon, Lucia López Corral, Rafael Hernani, Valentín Ortiz-Maldonado, Jaime Sanz, Ana Carolina Caballero Gonzalez, Luisa Guerra, José María Sánchez Pina, Alberto Mussetti, Alejandro Martin Garcia-Sancho, Mariana Bastos-Oreiro, Javier Delgado, Cecilia Carpio, Juan-Manuel Sancho, Antonio Pérez-Martinez, Pere Barba","doi":"10.1038/s41409-025-02722-y","DOIUrl":"10.1038/s41409-025-02722-y","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 12","pages":"1-4"},"PeriodicalIF":5.2,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-29DOI: 10.1038/s41409-025-02715-x
Raffaella Greco, Riccardo Saccardi, Marta Ponzano, Manuela Badoglio, Grzegorz Helbig, Marek Smilowski, Alice Mariottini, Joachim Burman, Kristina Carlson, Majid Kazmi, Paolo A. Muraro, Ian Gabriel, Barbara Withers, Jennifer Massey, Riccardo Varaldo, Matilde Inglese, Jaime Sanz, Sara Gil-Perotin, Basil Sharrack, Elisa Roldan, Chiara Nozzoli, Alessio Signori, Maria Pia Sormani, Tobias Alexander, John A. Snowden
Multiple Sclerosis (MS) is the most frequent autoimmune disease (AD) treated with autologous hematopoietic stem cell transplantation (HSCT). There are no prospective trials comparing the most used conditioning regimens, BEAM/Anti-thymocyte globulin (ATG) and cyclophosphamide (CYC)/ATG. Herein, we report a retrospective analysis of the EBMT database aimed to assess their risk/benefit ratio. We included 1114 MS patients who were conditioned with either BEAM/ATG or CYC/ATG. Neutrophil engraftment in BEAM/ATG- and CYC/ATG-treated patients occurred at a median time of 11 and 10 days after HSCT (p = 0.079). Overall, 2.0% of patients conditioned with BEAM/ATG and 1.0% with CYC/ATG died within 100 days from HSCT (p = 0.19). Overall, the incidence of NEDA (No-Evidence of Disease Activity) failure in BEAM/ATG and CYC/ATG at 5 years was 42.3% (95% CI: 36.3–48.8%) and 44.1% (95% CI: 30.8–60.1%), respectively (p = 0.081). No statistically significant differences between the two treatments [HR = 0.90 (95% CI = 0.61; 1.34), p = 0.60] were confirmed, when adjusting for disease type, disability at baseline and year of transplant. A clear difference between the regimens is lacking, both in terms of toxicity and efficacy, in this large population. Type of disease (relapsing/remitting vs progressive) is still the major determinant of neurological outcome.
{"title":"BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party","authors":"Raffaella Greco, Riccardo Saccardi, Marta Ponzano, Manuela Badoglio, Grzegorz Helbig, Marek Smilowski, Alice Mariottini, Joachim Burman, Kristina Carlson, Majid Kazmi, Paolo A. Muraro, Ian Gabriel, Barbara Withers, Jennifer Massey, Riccardo Varaldo, Matilde Inglese, Jaime Sanz, Sara Gil-Perotin, Basil Sharrack, Elisa Roldan, Chiara Nozzoli, Alessio Signori, Maria Pia Sormani, Tobias Alexander, John A. Snowden","doi":"10.1038/s41409-025-02715-x","DOIUrl":"10.1038/s41409-025-02715-x","url":null,"abstract":"Multiple Sclerosis (MS) is the most frequent autoimmune disease (AD) treated with autologous hematopoietic stem cell transplantation (HSCT). There are no prospective trials comparing the most used conditioning regimens, BEAM/Anti-thymocyte globulin (ATG) and cyclophosphamide (CYC)/ATG. Herein, we report a retrospective analysis of the EBMT database aimed to assess their risk/benefit ratio. We included 1114 MS patients who were conditioned with either BEAM/ATG or CYC/ATG. Neutrophil engraftment in BEAM/ATG- and CYC/ATG-treated patients occurred at a median time of 11 and 10 days after HSCT (p = 0.079). Overall, 2.0% of patients conditioned with BEAM/ATG and 1.0% with CYC/ATG died within 100 days from HSCT (p = 0.19). Overall, the incidence of NEDA (No-Evidence of Disease Activity) failure in BEAM/ATG and CYC/ATG at 5 years was 42.3% (95% CI: 36.3–48.8%) and 44.1% (95% CI: 30.8–60.1%), respectively (p = 0.081). No statistically significant differences between the two treatments [HR = 0.90 (95% CI = 0.61; 1.34), p = 0.60] were confirmed, when adjusting for disease type, disability at baseline and year of transplant. A clear difference between the regimens is lacking, both in terms of toxicity and efficacy, in this large population. Type of disease (relapsing/remitting vs progressive) is still the major determinant of neurological outcome.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 12","pages":"1628-1634"},"PeriodicalIF":5.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-025-02715-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-29DOI: 10.1038/s41409-025-02720-0
Benedetta Elena Di Majo, Mouad Abouqateb, Jacques-Emmanuel Galimard, Arnaud Dalissier, Giovanna Lucchini, Birgitta Versluys, Ludmila Zubarovskaya, Oana Mirci-Danicar, Charlotte Jubert, Sanjay Tewari, Robert Wynn, Sarah Lawson, Gerard Michel, Adriana Balduzzi, Rose-Marie Hamladji, Anne Sirvent, Ali Al-Ahmari, Fanny Rialland, Maura Faraci, Marc Ansari, Jean-Hugues Dalle, Charlotte Calvo, Vanderson Rocha, Eliane Gluckman, Katharina Kleinschmidt, Selim Corbacioglu, Krzysztof Kalwak, Annalisa Ruggeri
Hematopoietic stem cell transplantation (HCT) is the standard consolidation therapy for children with high-risk or relapsed acute myeloid leukemia (AML). In the absence of an human leukocyte antigen (HLA)-matched donor, both unrelated cord blood transplantation (UCBT) and haploidentical HCT with post-transplant cyclophosphamide (haplo-PTCy) serve as viable alternatives. This study analyzed outcomes of 254 pediatric AML patients (CR1/CR2) who underwent either single-unit UCBT (N = 127) without serotherapy or haplo-PTCy (N = 127) between 2011 and 2021. Propensity score weighting was applied to minimize baseline differences. With a median follow-up of 2.9 years, no significant differences were observed in overall survival, leukemia-free survival, relapse incidence, non-relapse mortality (NRM), or graft-versus-host disease (GVHD)-free relapse-free survival. However, UCBT recipients had a lower risk of chronic GVHD (7.1% vs. 19.8%; P = 0.019). These findings confirm comparable survival outcomes between UCBT and Haplo-PTCy. Given the higher risk of cGVHD in haplo-PTCy, further research is needed to refine GVHD prevention strategies while maintaining relapse-free survival. Both approaches remain safe and readily available alternatives for pediatric AML patients lacking matched donors.
造血干细胞移植（HCT）是儿童高风险或复发急性髓性白血病（AML）的标准巩固治疗。在没有人类白细胞抗原（HLA）匹配供体的情况下，非亲属脐带血移植（UCBT）和移植后单倍体环磷酰胺（单倍体- ptcy）的单倍体脐带血移植（HCT）都是可行的选择。该研究分析了2011年至2021年期间接受单单位UCBT （N = 127）无血清治疗或单倍- ptcy （N = 127）治疗的254例儿科AML患者（CR1/CR2）的结果。倾向得分加权用于最小化基线差异。中位随访时间为2.9年，在总生存期、无白血病生存期、复发率、非复发死亡率（NRM）或移植物抗宿主病（GVHD）无复发生存期方面没有观察到显著差异。然而，UCBT接受者发生慢性GVHD的风险较低（7.1% vs. 19.8%; P = 0.019）。这些发现证实了UCBT和haploi - ptcy之间可比较的生存结果。鉴于单倍型ptcy患者发生cGVHD的风险较高，需要进一步研究在保持无复发生存期的同时，完善GVHD预防策略。对于缺乏匹配供体的儿科AML患者，这两种方法都是安全且容易获得的替代方法。
{"title":"Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP","authors":"Benedetta Elena Di Majo, Mouad Abouqateb, Jacques-Emmanuel Galimard, Arnaud Dalissier, Giovanna Lucchini, Birgitta Versluys, Ludmila Zubarovskaya, Oana Mirci-Danicar, Charlotte Jubert, Sanjay Tewari, Robert Wynn, Sarah Lawson, Gerard Michel, Adriana Balduzzi, Rose-Marie Hamladji, Anne Sirvent, Ali Al-Ahmari, Fanny Rialland, Maura Faraci, Marc Ansari, Jean-Hugues Dalle, Charlotte Calvo, Vanderson Rocha, Eliane Gluckman, Katharina Kleinschmidt, Selim Corbacioglu, Krzysztof Kalwak, Annalisa Ruggeri","doi":"10.1038/s41409-025-02720-0","DOIUrl":"10.1038/s41409-025-02720-0","url":null,"abstract":"Hematopoietic stem cell transplantation (HCT) is the standard consolidation therapy for children with high-risk or relapsed acute myeloid leukemia (AML). In the absence of an human leukocyte antigen (HLA)-matched donor, both unrelated cord blood transplantation (UCBT) and haploidentical HCT with post-transplant cyclophosphamide (haplo-PTCy) serve as viable alternatives. This study analyzed outcomes of 254 pediatric AML patients (CR1/CR2) who underwent either single-unit UCBT (N = 127) without serotherapy or haplo-PTCy (N = 127) between 2011 and 2021. Propensity score weighting was applied to minimize baseline differences. With a median follow-up of 2.9 years, no significant differences were observed in overall survival, leukemia-free survival, relapse incidence, non-relapse mortality (NRM), or graft-versus-host disease (GVHD)-free relapse-free survival. However, UCBT recipients had a lower risk of chronic GVHD (7.1% vs. 19.8%; P = 0.019). These findings confirm comparable survival outcomes between UCBT and Haplo-PTCy. Given the higher risk of cGVHD in haplo-PTCy, further research is needed to refine GVHD prevention strategies while maintaining relapse-free survival. Both approaches remain safe and readily available alternatives for pediatric AML patients lacking matched donors.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 12","pages":"1635-1641"},"PeriodicalIF":5.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-025-02720-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：